CHOosing Interventions that are Cost Effective (WHO-CHOICE)

AMR B: Cost effectiveness results for Blindness

This Table provides summary results of the total population-level costs, effects and cost-effectiveness for the selected WHO sub-region and risk factor / disease for the year 2000.

KEY
I$ - International Dollars
Program Costs include costs of administration, media, training etc
Patient Costs include costs of hospital visits, drugs, etc
Incremental cost-effectiveness ratio (ICER) is defined as the incremental change in cost, divided by the incremental change in effectiveness. ICERs are reported for the successive set of interventions that would be selected at expanding levels of resource availability, starting with the intervention with the lowest cost per DALY averted, then moving to the next most cost-effective combination intervention out of the remaining available set of interventions.
Dominated is used to denote an intervention that is more costly and/or less effective than other, more efficient (single or combined) interventions; i.e. dominated interventions do not appear on the expansion path of most cost-effective strategies.


Interventions:Codes_and_Descriptions Coverage Cost per year (I$, millions) per one million_population [i.e. cost per capita] % Program costs % Patient costs DALYs averted per year per one million_population Average Cost per DALY averted Incremental Cost per DALY averted
CTR-1: Intra-capsular Cataract extraction using aphakic glasses (50%) 50% 0.41 69% 31% 1,174 350 Dominated
CTR-2: Intra-capsular Cataract extraction using aphakic glasses (80%) 80% 0.49 58% 42% 1,893 261 Dominated
CTR-3: Intra-capsular Cataract extraction using aphakic glasses (95%) 95% 0.57 57% 43% 2,257 254 Dominated
CTR-4: Extra-capsular Cataract extraction with posterior chamber lens implant (50%) 50% 0.41 69% 31% 2,157 188 Dominated
CTR-5: Extra-capsular Cataract extraction with posterior chamber lens implant (80%) 80% 0.49 59% 41% 3,501 139 Dominated
CTR-6: Extra-capsular Cataract extraction with posterior chamber lens implant (95%) 95% 0.57 58% 42% 4,188 135 135
TRC-1: Mass treatment of trachoma with tetracycline ointment (at 50%, 80% and 95% coverage) ALL 1.04 62% 38% 9 113,441 Dominated
TRC-2: Mass treatment of trachoma with azithromycin (at 50%, 80% and 95% coverage) ALL 1.68 38% 62% 46 36,202 Dominated
TRC-3: Targeted treatment of trachoma with azithromycin (at 50%, 80% and 95% coverage) ALL 2.55 25% 75% 33 77,951 Dominated
TRC-4: Targeted treatment of trachoma with surgery (at 80% of current prevalence) 80% 0.05 31% 69% 1,016 49 49
TRC-5: Combination (TRC1 + TRC4) 1.09 61% 39% 1,025 1,064 Dominated
TRC-6: Combination (TRC2+ TRC4) 1.73 38% 62% 1,062 1,627 36,202
TRC-7: Combination (TRC3 + TRC4) 2.60 25% 75% 1,048 2,482 Dominated
Share